Qiagen NV represents a strong dedication to innovation, collaboration, and integrity. With a focus on providing cutting-edge solutions for molecular diagnostics and life sciences research, Qiagen NV is committed to improving patient outcomes and advancing healthcare globally. The company's corporate philosophy centers around relentlessly pursuing scientific breakthroughs and enabling scientists and healthcare professionals to make impactful discoveries. By leveraging their expertise in nucleic acid sample preparation and analysis, Qiagen NV aims to empower researchers and clinicians in their quest for improved diagnostics and personalized medicine. Emphasizing excellence, Qiagen NV continues to drive innovation and contribute to the betterment of global health.

Qiagen NV is primarily present in various countries and regions globally. The company has a significant presence in the United States, Germany, the Netherlands, China, and Switzerland, among others. With its headquarters in Germany, Qiagen NV operates in over 35 countries, serving customers in diverse regions and markets. By focusing on innovative molecular testing solutions, Qiagen NV is committed to improving healthcare outcomes and enabling scientific advancements worldwide.

Qiagen NV has achieved numerous significant milestones throughout its history. Some of these notable achievements include the development of innovative molecular sample and assay technologies, which have revolutionized the field of life sciences. The company has consistently delivered solutions that enable researchers and scientists worldwide to make groundbreaking discoveries and advancements in genomics, proteomics, and cellular analysis. Qiagen NV has also expanded its global presence by establishing strategic collaborations and partnerships, enhancing its product portfolio, and consistently delivering strong financial performance. These achievements reflect Qiagen NV's dedication to innovation, scientific excellence, and commitment to addressing the evolving needs of its customers in the life sciences industry.

Qiagen NV is a leading global provider of sample and assay technologies in the field of molecular diagnostics, applied testing, and academic research. Founded in 1984, Qiagen has a rich history of developing innovative solutions for the life sciences industry. The company offers a broad range of products and services including sample preparation, DNA sequencing, and genetic testing. With a strong focus on molecular biology and bioinformatics, Qiagen has established itself as a trusted partner for researchers, healthcare professionals, and pharmaceutical companies worldwide. Over the years, Qiagen has consistently delivered high-quality products, driving advancements in genomics and personalized medicine.

The main competitors of Qiagen NV in the market are Thermo Fisher Scientific Inc., Illumina Inc., and Becton, Dickinson and Company.

Qiagen NV is primarily active in the biotechnology and life sciences industries.

The business model of Qiagen NV focuses on providing innovative solutions for molecular testing and diagnostics. Qiagen NV specializes in sample and assay technologies that enable researchers and healthcare professionals to extract, isolate, and purify nucleic acids from biological samples. They offer a comprehensive portfolio of products and services that cater to various applications, including insights into diseases, personalized healthcare, and forensic analysis. By leveraging their expertise in molecular biology and bioinformatics, Qiagen NV aims to contribute to the advancement of diagnostics, research, and precision medicine.

De Qiagen K/W is 19,30.

De Qiagen KUV is 4,50.

De AlleAktien Kwaliteitsscore voor Qiagen is 3/10.

De verwachte Qiagen omzet is 2,04 mld. USD.

De verwachte Qiagen winst is 476,41 mln. USD.

Qiagen NV is a biotechnology company based in the Netherlands that specializes in the production of medical and laboratory equipment. The company offers a wide range of products and services, including the discovery and validation of biomarkers, the isolation of DNA and RNA, and the performance of gene expression analysis. This article describes the business model of Qiagen NV, including its various divisions and products.

Qiagen keert een dividend van 0 USD uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor Qiagen of het bedrijf keert geen dividend uit.

De ISIN van Qiagen is NL0012169213.

Het WKN van Qiagen is A2DKCH.

De ticker van Qiagen is QGEN.

Binnen de laatste 12 maanden betaalde Qiagen een dividend van 1,08 USD . Dit komt overeen met een dividendrendement van ongeveer 2,63 %. Voor de komende 12 maanden zal Qiagen naar verwachting een dividend van 0 USD betalen.

De dividendrendement van Qiagen is momenteel 2,63 %.

Qiagen betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden februari, februari, februari, februari.

Qiagen betaalde de afgelopen 5 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0 USD verwacht. Dit komt overeen met een dividendrendement van 0 %.

Qiagen wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van Qiagen van 1-2-2024 ter hoogte van 1,32 USD te ontvangen, moest je het aandeel voor de ex-datum op 30-1-2024 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 1-2-2024.

In het jaar 2023 heeft Qiagen 0 USD aan dividenden uitgekeerd.

De dividenden van Qiagen worden in USD uitgekeerd.